Registration is a 2-step process!
Select 'ENROLL NOW' to register and gain access to the link that will allow you to complete part 2 of the 2-step registration process.
Wednesday, February 3, 2021 (1:00PM - 2:00PM ET)
Pre-registration is required to participate. This activity is available to members only.
During this learning activity, the speakers will review the overuse of basal insulin in lieu of adding injectable bolus options, known as overbasalization. This is commonly seen in many patients with type 2 diabetes. Additionally, the speakers will discuss how this plays a role within clinical inertia, the lack of intensifying treatment despite not achieving the A1C goal. The discussion will provide the audience with the knowledge of current practice, as well as tools to help play an integral role in healthcare delivery to overcome these challenges.
At the completion of this knowledge-based activity, pharmacists will be able to:
- Define overbasalization and clinical inertia.
- Discuss the multifactorial reasons for overbasalization and clinical inertia.
- Discuss the consequences of failing to intensify therapy to patients with type 2 diabetes.
- Describe the evidence available regarding utilization of beneficial bolus agents in the management of type 2 diabetes mellitus.
- Recommend appropriate therapy intensification for patients with type 2 diabetes mellitus currently on basal insulin.
Activity type: Knowledge-based
Target Audience: Pharmacists
Learning level: 1
The American Pharmacists Association is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour of CPE credit (0.1 CEU). The ACPE Universal Activity Number for this activity is 0202-0000-21-117-L01-P.
To obtain credit for Avoid Overbasalization and Clinical Inertia in Patients with Type 2 Diabetes, attend the live activity, complete the evaluation, and claim credit. Participants need to have a valid pharmacist.com username and password to claim credit. After credit has been claimed, please visit CPE monitor for your transcript.
APhA's continuing pharmacy education policy allows two opportunities to successfully complete the continuing pharmacy education assessment. Please note that the questions may not appear in the same order as printed and only two attempts to pass the assessment will be granted. The current policy of the APhA Education Department is to not release the correct answers to any of our CPE tests. This policy is intended to maintain the integrity of the CPE activity and the assessment.
Initial release date: February 3, 2021
Expiration date: April 2, 2021 at 11:59PM Eastern Time - No credit can be claimed after this date
Avoid Overbasalization and Clinical Inertia in Patients with Type 2 Diabetes is a live continuing education activity for pharmacists developed by the American Pharmacists Association in conjunction with APhA’s Diabetes Management Special Interest Group (SIG). © 2021 American Pharmacists Association
Pooja Patel, PharmD, BCACP, CDCES; Kelsey Buckley, PharmD, BCACP; and APhA’s editorial staff declare no conflicts of interest or financial interests in any product or service mentioned in this activity, including grants, employment, gifts, stock holdings, and honoraria. For complete staff disclosures, please see the Education and Accreditation Information section at www.pharmacist.com/apha-disclosures.
This activity is exclusive to APhA members; there is no fee associated with this learning activity.
Computer and internet access are required to complete this activity. Please visit our website and view the Technology System Requirements to have a positive learning experience.
Overbasalization and Clinical Inertia in Patients with Type 2 Diabetes
|Date||2/3/2021 1:00:00 PM|
|Address||2215 Constitution Ave, NW|
|City||Washington||State||District of Columbia||Zip Code||20037|